Shares of MiniMed Group Inc (NASDAQ:MMED – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $21.6154.
A number of research firms recently issued reports on MMED. UBS Group began coverage on shares of MiniMed Group in a research report on Tuesday, July 28th. They set a “buy” rating and a $25.00 target price on the stock. Bank of America decreased their price target on shares of MiniMed Group from $27.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Piper Sandler reiterated a “neutral” rating and set a $16.00 price objective on shares of MiniMed Group in a report on Thursday, June 4th. Wells Fargo & Company reduced their target price on MiniMed Group from $26.00 to $22.00 and set an “overweight” rating for the company in a research note on Thursday, June 4th. Finally, Benchmark reaffirmed a “buy” rating on shares of MiniMed Group in a research note on Thursday, June 4th.
View Our Latest Stock Analysis on MiniMed Group
Hedge Funds Weigh In On MiniMed Group
MiniMed Group Stock Up 0.1%
NASDAQ MMED opened at $19.51 on Friday. The firm has a market capitalization of $5.49 billion and a PE ratio of -28.69. The business’s 50 day simple moving average is $17.25. MiniMed Group has a one year low of $10.65 and a one year high of $20.88.
MiniMed Group (NASDAQ:MMED – Get Free Report) last issued its quarterly earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The business had revenue of $837.00 million during the quarter. The firm’s revenue for the quarter was up 15.6% compared to the same quarter last year. As a group, sell-side analysts predict that MiniMed Group will post 0.66 earnings per share for the current year.
MiniMed Group Company Profile
We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.
Further Reading
- Five stocks we like better than MiniMed Group
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for MiniMed Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiniMed Group and related companies with MarketBeat.com's FREE daily email newsletter.
